Literature DB >> 28384644

Current Standard and Future Perspectives in the Treatment of Gastrointestinal Stromal Tumors.

Silke Cameron1, Alexander Beham, Hans-Ulrich Schildhaus.   

Abstract

The origin of gastrointestinal stromal tumors (GIST) from interstitial cells of Cajal or their precursor cells has been understood since the early 1990s. The first mutations within the KIT-gene have been described in the late 1990s. Even though these mutations were the breakthrough of small molecular therapy, we still do not know the factors responsible for their malignant transformation. Until then, we can only speak of recurrence risk. This review gives an introduction on the current understanding of GIST and highlights the remaining questions for diagnosis, tumor progression, and treatment in progressive disease.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Diagnosis and treatment; Gastrointestinal stromal tumors; Tyrosine kinase inhibitors 

Mesh:

Year:  2017        PMID: 28384644     DOI: 10.1159/000455835

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  3 in total

1.  A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study.

Authors:  Qinghong Guo; Qiang Li; Jiong Wang; Min Liu; Yuping Wang; Zhaofeng Chen; Yuwei Ye; Quanlin Guan; Yongning Zhou
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

2.  Inflammation-related indicators to distinguish between gastric stromal tumors and leiomyomas: A retrospective study.

Authors:  Yu-Hao Zhai; Zhi Zheng; Wei Deng; Jie Yin; Zhi-Gang Bai; Xiao-Ye Liu; Jun Zhang; Zhong-Tao Zhang
Journal:  World J Clin Cases       Date:  2022-01-14       Impact factor: 1.337

Review 3.  Gastrointestinal Stromal Tumors of the Small Intestine: Progress in Diagnosis and Treatment Research.

Authors:  Fangxing Peng; Yao Liu
Journal:  Cancer Manag Res       Date:  2020-05-25       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.